Fusion proteins, TrkC and ETV6-NTRK3, inhibit the tumor suppressor activity of TGF-β signaling through physical interaction between the tyrosine kinase domain of TrkC and TGF-β type II (TβRII) receptors [19,20]. Here, NTRK3 is linked to neoplasm.